NCT05223608 Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy
| NCT ID | NCT05223608 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Oscar Lambret |
| Condition | Solid Tumor, Adult |
| Study Type | INTERVENTIONAL |
| Enrollment | 651 participants |
| Start Date | 2022-03-03 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 651 participants in total. It began in 2022-03-03 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
ImmuCCo-1905 is a monocentric interventional study on patients treated by immunotherapy, which consist in establishment of a prospective clinic-biologic database over 5 years, associated with a biobank. This database will allow carrying out works aiming at assessing immunotherapy in real life situation.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Beginning a first immunotherapy by immune checkpoint inhibitor - anti-PD1 (Programmed cell Death protein-1), anti-PDL1 (Programmed cell Death protein-1 ligand), anti-CTLA4 (Cytotoxic T-Lymphocyte associated protein 4), as monotherapy or in combination, in the Centre Oscar Lambret (COL) * In neo-adjuvant, adjuvant, recurrence or metastatic situation * Suffering from solid tumor histologically documented * Signed written informed consent * Patient covered by the French " "Social Security" regime If the patient is already enrolled in clinical trial involving immunotherapy, the agreement of the sponsor of this new trial will be sought before his/her inclusion. Exclusion Criteria: * Pregnant or breastfeeding women * Patient already treated by immunotherapy by immune checkpoint inhibitor * Person under guardianship * Inability to comply with medical follow-up of the trial (geographical, social or psychic reasons)
Contact & Investigator
Alexandra FORESTIER, MD
PRINCIPAL INVESTIGATOR
Centre Oscar Lambret
Frequently Asked Questions
Who can join the NCT05223608 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Solid Tumor, Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05223608 currently recruiting?
Yes, NCT05223608 is actively recruiting participants. Contact the research team at promotion@o-lambret.fr for enrollment information.
Where is the NCT05223608 trial being conducted?
This trial is being conducted at Lille, France.
Who is sponsoring the NCT05223608 clinical trial?
NCT05223608 is sponsored by Centre Oscar Lambret. The principal investigator is Alexandra FORESTIER, MD at Centre Oscar Lambret. The trial plans to enroll 651 participants.